Nurix swings to quarterly net income of 549.81 million; revenue jumps to 673.06 million

By Public Technologies
  • Nurix reported revenue of $673.06 million for the three months ended Aug. 31, 2026, up 8,426% year over year.
  • Net income swung to $549.81 million, or $4.73 per diluted share, from a net loss of $86.42 million.
  • Research and development expenses fell to $79.26 million, while general and administrative expenses rose to $34.35 million.
  • The revenue increase was primarily due to $653.16 million of license revenue from the Roche collaboration and a $10 million Sanofi milestone.
  • Management highlighted first patient dosed in the Phase 3 DAYBreak CLL-306 trial and cash of $1.1 billion with runway into 2H 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610121605PRIMZONEFULLFEED9843991) on October 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.